Reports link GLP-1 medications like Ozempic and Mounjaro to vision loss, prompting concerns over their safety.

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for its weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide).

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro, may be an effective alternative to painful daily treatment for a rare disorder, according to research published Jan. 29 in ...

or tirzepatide (Mounjaro, Zepbound). A survey of neuro-ophthalmologists turned up seven cases of nonarteritic ischemic anterior optic neuropathy (NAION), one case of bilateral papillitis ...

Ophthalmic complications were observed in patients using semaglutide and tirzepatide, but a causal link was not established. The study included nine patients, with conditions like nonarteritic ...

This represents the first time that Lexaria worked with the drug tirzepatide, which is sold by Eli Lilly under the brand names Zepbound® and Mounjaro®. Much like liraglutide, tirzepatide is also ...

Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus while tirzepatide is the active ingredient in Mounjaro and Zepbound. Publishing in the Journal of the American Medical Association ...

“Each injection is painful.” In the recent study, researchers explored if the diabetes and obesity drug tirzepatide (the active ingredient in Zepbound and Mounjaro) could improve CGL, as it improves ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may increase the risk of pulmonary aspiration among patients undergoing surgery ...

For patients looking for a sustainable weight-loss treatment, the service's clinicians can prescribe a Mounjaro KwikPen ... It uses an ingredient called tirzepatide to stimulate two hormonal ...